QYBX.US Qian Yuan Baixing Inc
- Market cap
- USD 834K
- P/E
- -
- P/B
- -
- ROE
- 21.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QYBX.US undervalued?
Graham numberThe Graham number of Qian Yuan Baixing Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Qian Yuan Baixing Inc fundamental analysis
No fundamental analysis for Qian Yuan Baixing Inc yet.
Qian Yuan Baixing Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Qian Yuan Baixing Inc
Qian Yuan Baixing, Inc. focuses on the medical equipment diagnostic and biotech business. It is also involved in selling goods and services on the internet and the production, processing, distribution and professional technical consulting services of soft capsules for supplements. The company was formerly known as MDCorp. and changed its name to Qian Yuan Baixing, Inc. in May 2018. Qian Yuan Baixing, Inc. was incorporated in 2005 and is based in Seattle, Washington.
Full company profileQian Yuan Baixing Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Qian Yuan Baixing Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | 181K | 460K | 4.89M | 4.28M | 2.31M | 2.79M |
| Gross Profit | - | - | - | - | - | 153K | 366K | 1.01M | 864K | 495K | 879K |
| Operating Income | -5.77K | -136K | -89.0K | -77.6K | -16.5K | 70.2K | 7.48K | 354K | 307K | 113K | 439K |
| EBITDA | -5.77K | -136K | -89.0K | -77.6K | -16.5K | 307K | 9.98K | 1.10M | 487K | 191K | 491K |
| Net Income | -5.77K | -139K | -94.0K | -82.6K | -21.5K | 63.6K | 2.19K | 1.04M | 300K | 127K | 368K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | - | 40.6K | 9.32K | - | 250.00 | 294K | 256K | 1.62M | 2.59M | 2.31M | 2.64M |
| Total Liabilities | - | 103K | 148K | - | 243K | 374K | 341K | 678K | 1.38M | 912K | 886K |
| Shareholders' Equity | - | -62.7K | -139K | - | -243K | -80.6K | -85.1K | 942K | 1.21M | 1.40M | 1.75M |
| Cash & Short-term Investments | - | 40.6K | - | - | - | 3.48K | 42.6K | 329K | 1.16M | 1.38M | 1.60M |
| Total Debt | - | 100K | 100K | - | 100K | 100K | 100K | 100K | 100K | 100K | 100K |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | -66.0K | -76.3K | -66.7K | - | -9.47K | 125K | 305K | 1.20M | -128K | 314K |
| Capital Expenditure | - | 0.00 | 0.00 | 0.00 | - | 7.87K | 28.9K | 6.76K | 79.2K | 4.43K | 141K |
| Free Cash Flow | - | -66.0K | -76.3K | -66.7K | - | -17.3K | 96.5K | 298K | 1.12M | -132K | 173K |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | - | - | 110.5% | 24.9% | 9.1% | 21.0% |
| ROA | - | -342.2% | -1,008.9% | - | -8,615.6% | 21.7% | 0.9% | 64.3% | 11.6% | 5.5% | 13.9% |
| Net Profit Margin | - | - | - | - | - | 35.2% | 0.5% | 21.3% | 7.0% | 5.5% | 13.2% |
| Debt to Equity | - | - | - | - | - | - | - | 0.11x | 0.08x | 0.07x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Qian Yuan Baixing Inc dividends
Qian Yuan Baixing Inc has not paid dividends in the last 9 fiscal years.
Who owns Qian Yuan Baixing Inc
Ownership data of Qian Yuan Baixing Inc is not available yet.
Qian Yuan Baixing Inc company profile
- Company name
- Qian Yuan Baixing Inc
- Ticker
- QYBX.US
- Exchange
- USA Stocks
- Sector
- Consumer Cyclical
- Industry
- Capital Markets
- Employees
- 15
- Fiscal year end
- December
- Address
- 601 Union Street, Seattle, WA, United States, 98101
- Phone
- 206-923-9200
- Website
- -
About Qian Yuan Baixing Inc
Qian Yuan Baixing, Inc. focuses on the medical equipment diagnostic and biotech business. It is also involved in selling goods and services on the internet and the production, processing, distribution and professional technical consulting services of soft capsules for supplements. The company was formerly known as MDCorp. and changed its name to Qian Yuan Baixing, Inc. in May 2018. Qian Yuan Baixing, Inc. was incorporated in 2005 and is based in Seattle, Washington.
Qian Yuan Baixing Inc management
1- Mr. Tim AlfordChief Operating Officer and Director · born 1961